World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 2508346

Number of visits today: 673

Number of downloads: 1690162

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Sacco R, Granito A, Bargellini I, Zolfino T, Saitta C, Marzi L, Tapete G, Bresci G, Marinelli S, Tovoli F, Attardo S, Rossi M, Urbani L, Marchi S, Buccianti P, Cabibbo G. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncol 2018;14:3049-58. [PMID: 30091371 DOI: 10.2217/fon-2018-0281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]

For:

Sacco R, Granito A, Bargellini I, Zolfino T, Saitta C, Marzi L, Tapete G, Bresci G, Marinelli S, Tovoli F, Attardo S, Rossi M, Urbani L, Marchi S, Buccianti P, Cabibbo G. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncol 2018;14:3049-58. [PMID: 30091371 DOI: 10.2217/fon-2018-0281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]

Number	Citing Articles
1	Desai GS, Pande PM, Narkhede RA, Wagle PK. Multimodality Management of Ruptured Large Hepatocellular Carcinoma and Its Recurrence: Rupture at Presentation Should Not Rupture Hope of Long-Term Survival. Surg J (N Y) 2020;6:e112-7. [PMID: 32566748 DOI: 10.1055/s-0040-1710530] [Reference Citation Analysis]
2	Carballo-Folgoso L, Álvarez-Velasco R, Lorca R, Castaño-García A, Cuevas J, González-Diéguez ML, Martín M, Álvarez-Navascués C, Cadahía V, Morís C, Rodríguez M, Varela M. Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. Liver Int 2021;41:2200-11. [PMID: 33966333 DOI: 10.1111/liv.14941] [Reference Citation Analysis]
3	Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G, Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 2019;71:1175-83. [PMID: 31449860 DOI: 10.1016/j.jhep.2019.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
4	Casadei-Gardini A, Dadduzio V, Rovesti G, Cabibbo G, Vukotic R, Rizzato MD, Orsi G, Rossi M, Guarneri V, Lonardi S, D'agostino D, Celsa C, Andreone P, Zagonel V, Scartozzi M, Cascinu S, Cucchetti A. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (Baltimore) 2020;99:e19958. [PMID: 32481366 DOI: 10.1097/MD.0000000000019958] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]